“Breakthrough Cardiology Treatment: European Hospitals Led by Puerta de Hierro Participate”

2023-05-20 15:08:45

Cardiology

Six European hospitals led by Puerta de Hierro participate

The antibody manages to remove the amyloid protein already deposited and opens the door to new drugs for the increasingly frequent cardiac amyloidosis due to transthyretin.

On the left, amyloid plaques in the heart of a patient. On the right, the same patient with less amyloid one year following taking the drug. Signature: Puerta de Hierro University Hospital-CNIC.

1684623772
#Spanish #researchers #lead #trial #drug #reverses #stiff #heart #syndrome

Leave a Replay